The Alopecia Areata Severity and Morbidity Index (ASAMI) Study
This preliminary global consensus survey study identifies factors associated with alopecia areata severity beyond scalp hair loss, supporting the development of a multicomponent severity tool that would successfully measure various disease outcomes. (Source: JAMA Dermatology)
Source: JAMA Dermatology - February 7, 2024 Category: Dermatology Source Type: research
Support Group Participation Among Patients With Alopecia Areata
This cross-sectional study describes support group use and experience among patients with alopecia areata. (Source: JAMA Dermatology)
Source: JAMA Dermatology - February 7, 2024 Category: Dermatology Source Type: research
Tick bite-induced alopecia areata-like effluvium
Australas J Dermatol. 2024 Feb 4. doi: 10.1111/ajd.14215. Online ahead of print.NO ABSTRACTPMID:38311815 | DOI:10.1111/ajd.14215 (Source: The Australasian Journal of Dermatology)
Source: The Australasian Journal of Dermatology - February 5, 2024 Category: Dermatology Authors: Rodrigo Pe ñuelas Leal Andr és Grau Echevarría Carolina Labrandero Hoyos Jorge Magdaleno Tapial Altea Esteve Mart ínez Source Type: research
Examining the link between TNF inhibition and alopecia areata using Mendelian randomization
(Source: Clinical Rheumatology)
Source: Clinical Rheumatology - February 1, 2024 Category: Rheumatology Source Type: research
The Role of Histamine and Histamine H3/4 receptors in Cytokine synthesis in Alopecia Areata Associated with Atopy
This study assesses cytokine synthesis by peripheral blood mononuclear cells (PBMC) in AA patients with and without atopy. (Source: Journal of Allergy and Clinical Immunology)
Source: Journal of Allergy and Clinical Immunology - February 1, 2024 Category: Allergy & Immunology Authors: Galina Tereshenko, Nikolay Potekaev, Aida Gadzhigoroeva, Olga Zhukova, Roman Khanferyan, Lawrence Dubuske Source Type: research
Increase in CD8+ effector memory T cells re-expressing CD45RA correlates with intractability of severe alopecia areata
Rapidly progressive alopecia areata (RP-AA) is characterized by sudden and excessive dystrophic anagen hair loss typically involving entire scalp (Fukuyama et al., 2022). To directly suppress perifollicular autoreactive cytotoxic CD8+ T cell infiltration, intravenous corticosteroid pulse therapy (IV-PT) has been preferentially performed for acute phase RP-AA (Fukuyama et al., 2022, Kinoshita-Ise et al., 2023). Treatment responses to IV-PT are variable and requires around half a year to be adequately assessed (Sato et al., 2021). (Source: Journal of Investigative Dermatology)
Source: Journal of Investigative Dermatology - January 25, 2024 Category: Dermatology Authors: Ryo Takahashi, Misaki Kinoshita-Ise, Yoshimi Yamazaki, Masahiro Fukuyama, Manabu Ohyama Tags: Letters to the Editor Source Type: research
Alopecia Areata
This Patient Page describes the symptoms, diagnosis, and treatment of alopecia areata. (Source: JAMA Dermatology)
Source: JAMA Dermatology - January 24, 2024 Category: Dermatology Source Type: research
Virtual Bioequivalence Assessment of Ritlecitinib Capsules with Incorporation of Observed Clinical Variability Using a Physiologically Based Pharmacokinetic Model
This study demonstrates a PBPK model –based biowaiver for a clinical BE study while introducing a novel method to integrate clinically observed ICV into VBE trials with PBPK models. Trial registration: NCT02309827, NCT02684760, NCT04004663, NCT04390776, NCT05040295, NCT05128058.Graphical Abstract (Source: The AAPS Journal)
Source: The AAPS Journal - January 24, 2024 Category: Drugs & Pharmacology Source Type: research
Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program
ConclusionsRitlecitinib is well tolerated with an acceptable safety profile up to 24 months in patients aged ≥ 12 years with AA (video abstract and graphical plain language summary available).Trial RegistriesClinicalTrials.gov: NCT02974868 (date of registration: 11/29/2016), NCT04517864 (08/18/2020), NCT03732807 (11/07/2018), and NCT04006457 (07/05/2019). (Source: American Journal of Clinical Dermatology)
Source: American Journal of Clinical Dermatology - January 23, 2024 Category: Dermatology Source Type: research
Baricitinib Therapy for Moderate to Severe Alopecia Areata: A Retrospective Review of 95 Japanese Patients
Acta Derm Venereol. 2024 Jan 22;104:adv18348. doi: 10.2340/actadv.v104.18348.NO ABSTRACTPMID:38248913 | PMC:PMC10811547 | DOI:10.2340/actadv.v104.18348 (Source: Acta Derm Venereol A...)
Source: Acta Derm Venereol A... - January 22, 2024 Category: Dermatology Authors: Takafumi Numata Ryokichi Irisawa Miho Mori Masaki Uchiyama Kazutoshi Harada Source Type: research
Baricitinib Therapy for Moderate to Severe Alopecia Areata: A Retrospective Review of 95 Japanese Patients
Acta Derm Venereol. 2024 Jan 22;104:adv18348. doi: 10.2340/actadv.v104.18348.NO ABSTRACTPMID:38248913 | PMC:PMC10811547 | DOI:10.2340/actadv.v104.18348 (Source: Acta Dermato-Venereologica)
Source: Acta Dermato-Venereologica - January 22, 2024 Category: Dermatology Authors: Takafumi Numata Ryokichi Irisawa Miho Mori Masaki Uchiyama Kazutoshi Harada Source Type: research
